Dovitinib (TKI-258)

For research use only.

Catalog No.S1018 Synonyms: CHIR-258

37 publications

Dovitinib (TKI-258) Chemical Structure

CAS No. 405169-16-6

Dovitinib (TKI258, CHIR258) is a multitargeted RTK inhibitor, mostly for class III (FLT3/c-Kit) with IC50 of 1 nM/2 nM, also potent to class IV (FGFR1/3) and class V (VEGFR1-4) RTKs with IC50 of 8-13 nM, less potent to InsR, EGFR, c-Met, EphA2, Tie2, IGF-1R and HER2 in cell-free assays. Phase 4.

Size Price Stock Quantity  
10mM (1mL in DMSO) EUR 187 In stock
EUR 167 In stock
EUR 265 In stock
EUR 461 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Dovitinib (TKI-258) has been cited by 37 publications

Purity & Quality Control

Choose Selective FLT3 Inhibitors

Biological Activity

Description Dovitinib (TKI258, CHIR258) is a multitargeted RTK inhibitor, mostly for class III (FLT3/c-Kit) with IC50 of 1 nM/2 nM, also potent to class IV (FGFR1/3) and class V (VEGFR1-4) RTKs with IC50 of 8-13 nM, less potent to InsR, EGFR, c-Met, EphA2, Tie2, IGF-1R and HER2 in cell-free assays. Phase 4.
Targets
FLT3 [1]
(Cell-free assay)
c-Kit [1]
(Cell-free assay)
FGFR1 [1]
(Cell-free assay)
VEGFR3/FLT4 [1]
(Cell-free assay)
FGFR3 [1]
(Cell-free assay)
1 nM 2 nM 8 nM 8 nM 9 nM
In vitro

Dovitinib potently inhibits the FGF-stimulated growth of WT and F384L-FGFR3-expressing B9 cells with IC50 of 25 nM. In addition, Dovitinib inhibits proliferation of B9 cells expressing each of the various activated mutants of FGFR3. Interestingly, there are minimal observed differences in the sensitivity of the different FGFR3 mutations to Dovitinib, with the IC50 ranging from 70 to 90 nM for each of the various mutations. IL-6-dependent B9 cells containing vector only (B9-MINV cells are resistant to the inhibitory activity of Dovitinib at concentrations up to 1 μM. Dovitinib inhibits cell proliferation of KMS11 (FGFR3-Y373C), OPM2 (FGFR3-K650E), and KMS18 (FGFR3-G384D) cells with IC50 of 90 nM (KMS11 and OPM2) and 550 nM, respectively. Dovitinib inhibits FGF-mediated ERK1/2 phosphorylation and induces cytotoxicity in FGFR3-expressing primary MM cells. BMSCs does confer a modest degree of resistance with 44.6% growth inhibition for cells treated with 500 nM Dovitinib and cultured on stroma compared with 71.6% growth inhibition for cells grown without BMSCs. Dovitinib inhibits proliferation of M-NFS-60, an M-CSF growth-driven mouse myeloblastic cell line with a median effective concentration (EC50) of 220 nM. [1] Treatment of SK-HEP1 cells with Dovitinib results in a dose-dependent reduction in cell number and G2/M phase arrest with reduction in the G0/G1 and S phases, inhibition of anchorage-independent growth and blockage of bFGF-induced cell motility. The IC50 for Dovitinib in SK-HEP1 cells is approximately 1.7 μM. Dovitinib also significantly reduces the basal phosphorylation levels of FGFR-1, FGFR substrate 2α (FRS2-α) and ERK1/2 but not Akt in both SK-HEP1 and 21-0208 cells. In 21-0208 HCC cells, Dovitinib significantly inhibits bFGF-induced phosphorylation of FGFR-1, FRS2-α, ERK1/2 but not Akt. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SupB15 M{TwRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnm4TWM2OD1yLkS0PUDPxE1? MnnhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{MEKwO|MoRjJ3MkCyNFc{RC:jPh?=
SupB15-R MkLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPPSVVKSzVyPUCuOVU5KM7:TR?= MnPDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{MEKwO|MoRjJ3MkCyNFc{RC:jPh?=
BaF3-pSRα NI\VSZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHHSWJ3UUN3ME2wMlY3QCEQvF2= NHS4OGg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUKwNlA4Oyd-MkWyNFIxPzN:L3G+
BaF3-p210Bcr-Abl NIXPV29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo[3TWM2OD1yLk[5NkDPxE1? MofrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{MEKwO|MoRjJ3MkCyNFc{RC:jPh?=
BaF3-p210Bcr-Abl-T315I NXnxcGJTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;tTmlEPTB;Mj62NlYh|ryP MnPHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{MEKwO|MoRjJ3MkCyNFc{RC:jPh?=
CCRF-CEM NG\XdpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHLTWM2OD1yLkO5PEDPxE1? M1nNfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkCyNFczLz5{NUKwNlA4OjxxYU6=
CEM/C2 M1WwdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LCUmlEPTB;MT6xNlUh|ryP MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJyMkC3Nkc,OjV{MEKwO|I9N2F-
Nalm-6 MoLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTBwM{iyJO69VQ>? NUH5RppVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyNFIxPzJpPkK1NlAzODd{PD;hQi=>
SEM-K2 MoDLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHlTWM2OD1yLkCyNkDPxE1? NUfHR4trRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyNFIxPzJpPkK1NlAzODd{PD;hQi=>
HB-1119 M1[3ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV25UmM5UUN3ME2wMlAzQCEQvF2= M1LyPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkCyNFczLz5{NUKwNlA4OjxxYU6=
RS4:11 MoD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTJwOEGg{txO MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJyMkC3Nkc,OjV{MEKwO|I9N2F-
Nalm-6 MXvBdI9xfG:|aYOgRZN{[Xl? NX[5[ndNOiEQvF2= M3LlXVI1NzR6IHi= MW\pcoR2[2W|IHHwc5B1d3OrczDy[ZN2dHSrbnegbY4h[WKxdYSgO|ImKG:oIHPlcIwh\GWjdHigZYZ1\XJiMkSgbEB1emWjdH3lcpQh[W6mIEixKUBi\nSncjC0PEBp NHjDW5k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUKwNlA4Oid-MkWyNFIxPzJ:L3G+
SEM-K2 NHvQbYRCeG:ydH;zbZMhSXO|YYm= MX6wMlEwOSEQvF2= Mm[wNlQhcA>? NF7leINqdmS3Y3XzJIViemy7IHHwc5B1d3OrczDv[kBUTU1vS{KgZ4VtdHNiYYSgNE4yKM7:TTDh[pRmeiB{NDDo M{G0OFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkCyNFczLz5{NUKwNlA4OjxxYU6=
HCT-116 Mly3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnzWYZKSzVyPUOuNFUxNjV6IN88US=> NITkfWo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NES5OVc2OCd-MkS0PVU4PTB:L3G+
HT-29 M3XhZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13UN2lEPTB;NT6yNU46OyEQvF2= MnHWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2OUW3OVAoRjJ2NEm1O|UxRC:jPh?=
SW-480 NUW2dlZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnT1TWM2OD12LkOzNE41PyEQvF2= NXX0THJvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0PVU4PTBpPkK0OFk2PzVyPD;hQi=>
CaCO2 MkDUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDpTWM2OD1|LkKzNE43PCEQvF2= M33UWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEm1O|UxLz5{NES5OVc2ODxxYU6=
LS174T NETGRYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPYTWM2OD12LkOzNE41PyEQvF2= NFjOXYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NES5OVc2OCd-MkS0PVU4PTB:L3G+
HEC-1A NUfyWJZSTnWwY4Tpc44hSXO|YYm= NXradFRsOC5yNT:wMlEwOC53IN88US=> MWO3NkBp NEXheIZk[XW|ZYOgZUBl\WO{ZXHz[UBqdiCVVFHUN{whTVKNLDDhcoQhSUuWIIDoc5NxcG:{eXzheIlwdg>? NXnn[5dbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0PVU4PTBpPkK0OFk2PzVyPD;hQi=>
AN3CA M32xXGZ2dmO2aX;uJGF{e2G7 Ml7vNE4xPS9yLkGvNE42KM7:TR?= MXu3NkBp M4XyWYNifXOnczDhJIRm[3KnYYPlJIlvKFOWQWSzMEBGWktuIHHu[EBCU1RicHjvd5Bpd3K7bHH0bY9v NVT2UHM4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0PVU4PTBpPkK0OFk2PzVyPD;hQi=>
MFE-296  MljSSpVv[3Srb36gRZN{[Xl? NFPKPI0xNjB3L{CuNU8xNjVizszN M2DGXVczKGh? MXjjZZV{\XNiYTDk[YNz\WG|ZTDpckBUXEGWMzygSXJMNCCjbnSgRWtVKHCqb4PwbI9zgWyjdHnvci=> M4G4[|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEm1O|UxLz5{NES5OVc2ODxxYU6=
UMC3 MkewR4VtdCCYaXHibYxqfHliQYPzZZk> MUmxMVExKM7:TR?= NYCzd29bPzJiaB?= MmXabY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> MkW0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR|MkW0OlEoRjJ2M{K1OFYyRC:jPh?=
5637 NUf3b3Y2S2WubDDWbYFjcWyrdImgRZN{[Xl? MX[xMVExKM7:TR?= NYTMRVFsPzJiaB?= NXHxboFEcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MnLoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR|MkW0OlEoRjJ2M{K1OFYyRC:jPh?=
HU456 MUXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MX[xMVExKM7:TR?= NU\UTo9YPzJiaB?= M4H0VIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN{NUS2NUc,OjR|MkW0OlE9N2F-
MGHU4 MV3D[YxtKF[rYXLpcIl1gSCDc4PhfS=> MnPENU0yOCEQvF2= NHnib4E4OiCq NXL5XZBGcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NInlfGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEOyOVQ3OSd-MkSzNlU1PjF:L3G+
HT1376 M3nJRmNmdGxiVnnhZoltcXS7IFHzd4F6 MV:xMVExKM7:TR?= M3vZbVczKGh? M{\jdYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz NFW4e2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEOyOVQ3OSd-MkSzNlU1PjF:L3G+
RT112 NEjCcHBE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M1Hk[FEuOTBizszN NH22[Wk4OiCq NVPTTFdvcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NUXrb|hRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzNlU1PjFpPkK0N|I2PDZzPD;hQi=>
T24 MUDD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NF7MUYQyNTFyIN88US=> MnuyO|IhcA>? MX3pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> NX3NU48yRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzNlU1PjFpPkK0N|I2PDZzPD;hQi=>
BFTC905 MmHuR4VtdCCYaXHibYxqfHliQYPzZZk> NWfSdYtOOS1zMDFOwG0> M1jHTFczKGh? M{TrZYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz M1LsSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{K1OFYyLz5{NEOyOVQ3OTxxYU6=
TCC-SUP MkPqR4VtdCCYaXHibYxqfHliQYPzZZk> MlqzNU0yOCEQvF2= MUm3NkBp M{DOSolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz NGDUfFY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEOyOVQ3OSd-MkSzNlU1PjF:L3G+
RT4 NFiydYRE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NVOxOYJROS1zMDFOwG0> M3vvRVczKGh? NWPrNZVYcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN{NUS2NUc,OjR|MkW0OlE9N2F-
HONE1 NW\F[phjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnIZXZNOC5zLUGwJO69VQ>? NGDuR5U1QMLiaB?= NELOR4lqdmS3Y3XzJGczN01iZHXsZZkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI> NXvWUYNDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyN|gxQTRpPkK0NlM5ODl2PD;hQi=>
HNE1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXWwMlEuOTBizszN M1Tzb|Q5yqCq NWHpZYlscW6mdXPld{BIOi:PIHTlcIF6KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ|OEC5OEc,OjR{M{iwPVQ9N2F-
CNE2  NGHX[4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TiWVAvOS1zMDFOwG0> MnKzOFjDqGh? NHPiVItqdmS3Y3XzJGczN01iZHXsZZkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI> NEPWOm09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEKzPFA6PCd-MkSyN|gxQTR:L3G+
C666-1 M2DPTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYi2T5BIOC5zLUGwJO69VQ>? MojOOFjDqGh? M1;CR4lv\HWlZYOgS|IwVSCmZXzhfUBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7ldi=> MlnZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{M{iwPVQoRjJ2MkO4NFk1RC:jPh?=
HeLa MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nUflAvOS1zMDFOwG0> M4\oZlI1KGh? MmDsbY5lfWOnczDHNk9OKGG{cnXzeEBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7ldi=> M4fDb|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkO4NFk1Lz5{NEKzPFA6PDxxYU6=
Hep3B NYLBVGpnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjINE4yNTFyIN88US=> NXXIbIZSOjRiaB?= NEnBTpFqdmS3Y3XzJGczyqCjcoLld5TDqA>? M2r3d|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkO4NFk1Lz5{NEKzPFA6PDxxYU6=
HepG2 M{nHNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DvVFQ5KGh? NGrTTolKSzVyPUKuO|I4KMLzIECuOFI6KM7:TR?= NVn2d|cxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1OFY2QTFpPkKzOVQ3PTlzPD;hQi=>
Hep3B M1r0W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DkSlQ5KGh? NV3TelNvUUN3ME20MlIzOyEEsTCwMlg{QSEQvF2= MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV2NkW5NUc,OjN3NE[1PVE9N2F-
PLC/PRF5 NE\wcIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjpbFE1QCCq NGXO[llKSzVyPUG2MlEzOCEEsTC0MlAxOSEQvF2= NIHlUmM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{W0OlU6OSd-MkO1OFY2QTF:L3G+
Huh7 NH3FeXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvqTY1FPDhiaB?= MV7JR|UxRTF3LkCwO{DDuSB5LkOzOEDPxE1? MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV2NkW5NUc,OjN3NE[1PVE9N2F-
HepG2 Ml;1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7LO|IhcA>? NFr0UHZKSzVyPUGuNlAxKMLzIECuNlI3KM7:TR?= MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV2NkW5NUc,OjN3NE[1PVE9N2F-
Hep3B MluyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\LVFczKGh? NInZ[WxKSzVyPUCuPFkzKMLzIECuNFQ1KM7:TR?= NHrJdHQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{W0OlU6OSd-MkO1OFY2QTF:L3G+
PLC/PRF5 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTaNlE4OiCq MVTJR|UxRTNwMUGwJOKyKDBwM{O3JO69VQ>? NYL4[JdlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1OFY2QTFpPkKzOVQ3PTlzPD;hQi=>
Huh7 MljDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3r1OVczKGh? MVjJR|UxRTNwOUiwJOKyKDBwOECzJO69VQ>? NH2yToM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{W0OlU6OSd-MkO1OFY2QTF:L3G+
MFE280 NXX5eJJXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{Tkc2lEPTB;MD60NkDDuSByLkC2JO69VQ>? M4nZdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NESzPFA2Lz5{M{S0N|gxPTxxYU6=
AN3CA NFzOfW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2q5UmlEPTB;MD61NEDDuSByLkGwJO69VQ>? MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzR2M{iwOUc,OjN2NEO4NFU9N2F-
HEC155 NWjWbZBOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIGxV5NKSzVyPUCuOlYhyrFiMD6wPUDPxE1? NFnhcJI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{S0N|gxPSd-MkO0OFM5ODV:L3G+
MFE296 M2K3bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HLfmlEPTB;MD62OkDDuSByLkG5JO69VQ>? NIrIdGI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{S0N|gxPSd-MkO0OFM5ODV:L3G+
SPAC1S NYHrXlVWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTBwN{egxtEhOC5yODFOwG0> M1i1OlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NESzPFA2Lz5{M{S0N|gxPTxxYU6=
RL952 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\aW2lEPTB;MD65N{DDuSByLkCxJO69VQ>? NGPXPZo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{S0N|gxPSd-MkO0OFM5ODV:L3G+
EN1 M1zlOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml6xTWM2OD1zLkCyJOKyKDBwMkWg{txO M4LiU|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NESzPFA2Lz5{M{S0N|gxPTxxYU6=
SNGII NGm5PWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmT2TWM2OD1zLkK0JOKyKDBwMkig{txO MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzR2M{iwOUc,OjN2NEO4NFU9N2F-
ISHIKAWA NX6zPYdLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrk[IpOUUN3ME2xMlMxKMLzIECuNVEh|ryP M2nobVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NESzPFA2Lz5{M{S0N|gxPTxxYU6=
HEC1A MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXrTWM2OD1zLkO0JOKyKDBwM{Cg{txO NV3kfYtrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0OFM5ODVpPkKzOFQ{QDB3PD;hQi=>
KLE Mnf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2ryd2lEPTB;MT6zO{DDuSByLkCyJO69VQ>? Mn;SQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2NEO4NFUoRjJ|NESzPFA2RC:jPh?=
SNGM MmHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTFwNEKgxtEhOC5zMzFOwG0> M2j3NlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NESzPFA2Lz5{M{S0N|gxPTxxYU6=
USPC2 NWHjXHNVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDvfppWUUN3ME2xMlYzKMLzIECuNFEh|ryP M2XpR|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NESzPFA2Lz5{M{S0N|gxPTxxYU6=
EN MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXP[mU{UUN3ME2xMlY3KMLzIECuNFEh|ryP M4Psd|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NESzPFA2Lz5{M{S0N|gxPTxxYU6=
MFE319 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXLTWM2OD1zLki3JOKyKDBwNEWg{txO NUDl[pNYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0OFM5ODVpPkKzOFQ{QDB3PD;hQi=>
EFE184 NHLqNIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHRTWM2OD1{LkC0JOKyKDBwMUOg{txO MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzR2M{iwOUc,OjN2NEO4NFU9N2F-
ECC1 NXrLW3hnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LsdGlEPTB;Mj6wO{DDuSByLkCxJO69VQ>? M{G2PFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NESzPFA2Lz5{M{S0N|gxPTxxYU6=
HEC1B M2HtcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PQR2lEPTB;Mj61O{DDuSByLkKzJO69VQ>? NHS2bo09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{S0N|gxPSd-MkO0OFM5ODV:L3G+
USPC1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPjTWM2OD1{Lk[wJOKyKDBwMUOg{txO NHv2Z3U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{S0N|gxPSd-MkO0OFM5ODV:L3G+
SPAC1L NHTCOVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYWxXIFyUUN3ME2zMlA3KMLzIEGuNVQh|ryP MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzR2M{iwOUc,OjN2NEO4NFU9N2F-
HUVEC NGjReJVE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MX6wMVI2KM7:TR?= M3PJV|czKGh? M2Xj[GROW09? Mn3ybY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> NHz3bVg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{KyPFAyPyd-MkOyNlgxOTd:L3G+
HMVEC NXzCTVZPS2WubDDWbYFjcWyrdImgRZN{[Xl? NVvBNlF5OC1{NTFOwG0> M{fKblczKGh? M3LNd2ROW09? MXrpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzJ{OECxO{c,OjN{MkiwNVc9N2F-
MHCC-97H Mlu1R4VtdCCYaXHibYxqfHliQYPzZZk> M2DiXlAuOjVizszN NUnXUm9TPzJiaB?= M3HqN2ROW09? MmXsbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> M4[3flxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|MkK4NFE4Lz5{M{KyPFAyPzxxYU6=
SMMC7721 NW[5S5N7S2WubDDWbYFjcWyrdImgRZN{[Xl? MWSwMVI2KM7:TR?= NIPPNW84OiCq MofWSG1UVw>? MXPpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> NHrG[3A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{KyPFAyPyd-MkOyNlgxOTd:L3G+
Huh-7 Mn3tRZBweHSxc3nzJGF{e2G7 MYCwMVEzNjVizszN NVS2[o05OjRiaB?= NELKS5JFVVORwrC= NEDD[45{\W6|aYTpfoV{KEiFQzDj[YxteyC2bzDUVmFKVC1iYX7kJJRq\2G2dYr1cYFjNWmwZIXj[YQh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz Ml7IQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{M{C0O|koRjJ{MkOwOFc6RC:jPh?=
Sk-Hep1 M4HDcGFxd3C2b4Ppd{BCe3OjeR?= MYKwMVEzNjVizszN NGjVOFIzPCCq NYrQ[415TE2VT9Mg M33PbZNmdnOrdHn6[ZMhUEOFIHPlcIx{KHSxIGTSRWlNNSCjbnSgeIlo[XS3eoXtZYIucW6mdXPl[EBieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MoLFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{M{C0O|koRjJ{MkOwOFc6RC:jPh?=
Hep3B MlG1RZBweHSxc3nzJGF{e2G7 NWXwR4RvOC1zMj61JO69VQ>? MYSyOEBp M4TUN2ROW00EoB?= NW[1cmdKe2Wwc3n0bZpmeyCKQ1OgZ4VtdHNidH:gWHJCUUxvIHHu[EB1cWejdIX6eY1i[i2rbnT1Z4VlKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NVuwT4lsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyN|A1PzlpPkKyNlMxPDd7PD;hQi=>
PLC5 NEPnTJFCeG:ydH;zbZMhSXO|YYm= MUGwMVEzNjVizszN NVPLdXN5OjRiaB?= M1nuOWROW00EoB?= NUTWeppxe2Wwc3n0bZpmeyCKQ1OgZ4VtdHNidH:gWHJCUUxvIHHu[EB1cWejdIX6eY1i[i2rbnT1Z4VlKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M4HGO|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MkOwOFc6Lz5{MkKzNFQ4QTxxYU6=
PLC5 MXTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M{\L[VAuOTVizszN MUC3NkBp Mm\RdoVlfWOnczDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5mesLi NVPMZ4dORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxPFA{ODhpPkKyNVgxOzB6PD;hQi=>
Hep3B M3[xeWNmdGxiVnnhZoltcXS7IFHzd4F6 NIj3c3kxNTF3IN88US=> NFPQZpE4OiCq NWHrOYlyemWmdXPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nctMg Mn20QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzOECzNFgoRjJ{MUiwN|A5RC:jPh?=
Sk-Hep1 M{TYfWNmdGxiVnnhZoltcXS7IFHzd4F6 MnnPNE0yPSEQvF2= NU\tcZF2PzJiaB?= M4jYRpJm\HWlZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XMEoB?= NYTr[op2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxPFA{ODhpPkKyNVgxOzB6PD;hQi=>
Huh-7 MX7D[YxtKF[rYXLpcIl1gSCDc4PhfS=> Ml7iNE0yPSEQvF2= NIDFdos4OiCq NFz1cmtz\WS3Y3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{wrC= MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjF6MEOwPEc,OjJzOECzNFg9N2F-
PLC5 NF\1TVZCeG:ydH;zbZMhSXO|YYm= MlTNNE0yPSEQvF2= MY[yOEBp M3TEVYlv[3KnYYPld{BieG:ydH;0bYMh[2WubDDk[YF1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5mesLi M4HqWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MUiwN|A5Lz5{MkG4NFMxQDxxYU6=
Hep3B M3jUdWFxd3C2b4Ppd{BCe3OjeR?= MnnuNE0yPSEQvF2= NX\jfXlROjRiaB?= MUnpcoNz\WG|ZYOgZZBweHSxdHnjJINmdGxiZHXheIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZLDqA>? MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjF6MEOwPEc,OjJzOECzNFg9N2F-
Sk-Hep1 M3SxXmFxd3C2b4Ppd{BCe3OjeR?= MUewMVE2KM7:TR?= M1nPZVI1KGh? NIXCV3pqdmO{ZXHz[ZMh[XCxcITveIlkKGOnbHyg[IVifGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XMEoB?= MonLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzOECzNFgoRjJ{MUiwN|A5RC:jPh?=
Huh-7 MYnBdI9xfG:|aYOgRZN{[Xl? M3jOPFAuOTVizszN NGXaTmszPCCq NYT2O2lZcW6lcnXhd4V{KGGyb4D0c5Rq[yClZXzsJIRm[XSqIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{wrC= MoLrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzOECzNFgoRjJ{MUiwN|A5RC:jPh?=
PLC5 NFj4bWVHfW6ldHnvckBCe3OjeR?= NVjQW|Z6OC1zMDFOwG0> NHLX[VczPCCq M1fLVYNifXOnczDkc5NmNWSncHXu[IVvfCCGTlGg[pJi\22nboTheIlwdg>? NFnNeYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkG4NFMxQCd-MkKxPFA{ODh:L3G+
Hep3B MkC4SpVv[3Srb36gRZN{[Xl? NYe5eXpnOC1zMDFOwG0> Mo\KNlQhcA>? NFmwXpZk[XW|ZYOg[I9{\S2mZYDlcoRmdnRiRF7BJIZz[WevZX70ZZRqd25? NWjESXFuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxPFA{ODhpPkKyNVgxOzB6PD;hQi=>
Sk-Hep1 MX\GeY5kfGmxbjDBd5NigQ>? M3TDPVAuOTBizszN M2jKUVI1KGh? NWn0O2I6[2G3c3XzJIRwe2VvZHXw[Y5l\W62IFTORUBnemGpbXXueIF1cW:w NWPSNJdERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxPFA{ODhpPkKyNVgxOzB6PD;hQi=>
Huh-7 M2jHbWZ2dmO2aX;uJGF{e2G7 MoTKNE0yOCEQvF2= MmDRNlQhcA>? MnPWZ4F2e2W|IHTvd4Uu\GWyZX7k[Y51KESQQTDmdoFodWWwdHH0bY9v Mn35QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzOECzNFgoRjJ{MUiwN|A5RC:jPh?=
SW780 NGTiN4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWK1JIQ> NHq2VpNKSzVyPUWwJI5O MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTFzOU[2NUc,OjFzMUm2OlE9N2F-
RT112 NIrMeWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVi1JIQ> MXjJR|UxRTF3IH7N MlLkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjFzMUm2OlEoRjJzMUG5OlYyRC:jPh?=
RT4 M2\YRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYG1JIQ> NXuyPYRnUUN3ME21JI5O MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTFzOU[2NUc,OjFzMUm2OlE9N2F-
JMSU1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XCd|Uh\A>? NYLkVlhLUUN3ME21NEBvVQ>? M1jPPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMUG5OlYyLz5{MUGxPVY3OTxxYU6=
J82 M{LKfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYS1JIQ> NH3rUJNKSzVyPUG0NFAhdk1? M3TwXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMUG5OlYyLz5{MUGxPVY3OTxxYU6=
97-7 M3X2VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH[2Row2KGR? MYPJR|UxRTFyMECgcm0> MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTFzOU[2NUc,OjFzMUm2OlE9N2F-
RT112 NUjufFljTnWwY4Tpc44hSXO|YYm= MU[1NFAhdk1? NYThO2JzOjRiaB?= M3\yRolv[3KnYYPld{B1cGVicILvdI9zfGmxbjDv[kBk\WyuczDpckBIOcLiYXPjc41x[W6rZXSgZpkh[SCmZXPy[YF{\SCrbjDTJIFv\CCJMj;NJJBp[XOncx?= NWDqeFhiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGxNVk3PjFpPkKxNVE6PjZzPD;hQi=>
RT4 NVT4c|V3TnWwY4Tpc44hSXO|YYm= M1L3ZlUxOCCwTR?= NHTFToIzPCCq M1jM[Ylv[3KnYYPld{B1cGVicILvdI9zfGmxbjDv[kBk\WyuczDpckBIOcLiYXPjc41x[W6rZXSgZpkh[SCmZXPy[YF{\SCrbjDTJIFv\CCJMj;NJJBp[XOncx?= M4TtblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMUG5OlYyLz5{MUGxPVY3OTxxYU6=
MGH-U3 M{S0cGZ2dmO2aX;uJGF{e2G7 M2jye|UxOCCwTR?= M133XVI1KGh? NH;k[WhqdmO{ZXHz[ZMhfGinIIDyc5BwenSrb36gc4Yh[2WubIOgbY4hTzIEoHHjZ49ueGGwaXXkJIJ6KGFiZHXjdoVie2ViaX6gV{BidmRiR{KvUUBxcGG|ZYO= NGDSWlE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUGxPVY3OSd-MkGxNVk3PjF:L3G+
SW780 MXjGeY5kfGmxbjDBd5NigQ>? NG\oRYE2ODBibl2= NHfVUIUzPCCq MmDzbY5kemWjc3XzJJRp\SCycn;wc5J1cW:wIH;mJINmdGy|IHnuJGcyyqCjY3PvcZBidmmnZDDifUBiKGSnY4LlZZNmKGmwIGOgZY5lKEd{L12gdIhie2W| MoXEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjFzMUm2OlEoRjJzMUG5OlYyRC:jPh?=
97-7 M17UV2Z2dmO2aX;uJGF{e2G7 M{PocVUxOCCwTR?= NGjmcZczPCCq MljybY5kemWjc3XzJJRp\SCycn;wc5J1cW:wIH;mJINmdGy|IHnuJGcyyqCjY3PvcZBidmmnZDDifUBiKGSnY4LlZZNmKGmwIGOgZY5lKEd{L12gdIhie2W| NXy2UFdNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGxNVk3PjFpPkKxNVE6PjZzPD;hQi=>
 J807C MnvTR4VtdCCYaXHibYxqfHliQYPzZZk> MX[wMVQxOCCwTR?= NVn5SJZuPDhiaB?= M{LoTolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPTV7OEixOEc,OTV3OUi4NVQ9N2F-
Y373C MmnqR4VtdCCYaXHibYxqfHliQYPzZZk> NGfzepUxNTRyMDDuUS=> M2jpfFQ5KGh? NH3Qe5ZqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NUnPZ49NRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUW1PVg5OTRpPkG1OVk5QDF2PD;hQi=>
K650E NIL4cI1E\WyuIG\pZYJqdGm2eTDBd5NigQ>? NVj4TYhyOC12MECgcm0> NFHyZ441QCCq M3;ZXolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPTV7OEixOEc,OTV3OUi4NVQ9N2F-
G384D NU\1c4hQS2WubDDWbYFjcWyrdImgRZN{[Xl? MVGwMVQxOCCwTR?= MUK0PEBp NGLpfmpqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NELmOFY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNUW5PFgyPCd-MUW1PVg5OTR:L3G+
F384L M3jGZ2NmdGxiVnnhZoltcXS7IFHzd4F6 MkTZNE01ODBibl2= MXK0PEBp MYTpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> NWLWO2hjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUW1PVg5OTRpPkG1OVk5QDF2PD;hQi=>
KMS11 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTEWo44OiCq M1LLZmlEPTB;OUCgcm0> NHH3dFU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNUW5PFgyPCd-MUW1PVg5OTR:L3G+
KMS18 NX7HNWNpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Moj5O|IhcA>? NW[4fWZlUUN3ME21OVAhdk1? NGDEd5Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNUW5PFgyPCd-MUW1PVg5OTR:L3G+
OPM2 NUGwZ4RXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVW1bZAxPzJiaB?= M2DEZWlEPTB;OUCgcm0> M4rjWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3NUm4PFE1Lz5zNUW5PFgyPDxxYU6=
H929 M2XVSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY[3NkBp NWraeGhPUUN3ME6gNlUxOCCwTR?= MnjoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTV3OUi4NVQoRjF3NUm4PFE1RC:jPh?=
8226 MmGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjCWFBCPzJiaB?= NXewWlk2UUN3ME6gNlUxOCCwTR?= NWn0O|dlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUW1PVg5OTRpPkG1OVk5QDF2PD;hQi=>
U266 NVLDN2dpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXX3SnJEPzJiaB?= NH3a[mJKSzVyPjCyOVAxKG6P NIWzeII9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNUW5PFgyPCd-MUW1PVg5OTR:L3G+
KM12L4A MmLBSpVv[3Srb36gZZN{[Xl? NWPm[FJ{UW6qaXLpeIlwdiCxZjDWSWdHWjJicHjvd5Bpd3K7bHH0bY9vKGW6cILld5Nm\CCrbjDoeY1idiCNTUGyUFRCKGOnbHzzJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrczygSWM2OD1yLkC0Ou69VQ>? M3jsW|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MUGzPFY3Lz5zOUGxN|g3PjxxYU6=
KM12L4A NUPJVnl3TnWwY4Tpc44h[XO|YYm= NWX3S2FSUW6qaXLpeIlwdiCxZjDQSGdHWmKndHGgdIhwe3Cqb4L5cIF1cW:wIHX4dJJme3OnZDDpckBpfW2jbjDLUVEzVDSDIHPlcIx{KFenc4Tldo4h[myxdDDhcoFtgXOrczygSWM2OD1yLkC1Ne69VQ>? NH3x[o09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUGxN|g3Pid-MUmxNVM5PjZ:L3G+
KM12L4A NUTXZnh2TnWwY4Tpc44h[XO|YYm= MWfJcohq[mm2aX;uJI9nKE[JRmKxJJBpd3OyaH;yfYxifGmxbjDlfJBz\XO|ZXSgbY4hcHWvYX6gT20yOkx2QTDj[YxteyCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZMtKEWFNUC9NE4yPjcQvF2= NGPWW2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUGxN|g3Pid-MUmxNVM5PjZ:L3G+
insect cells MUjGeY5kfGmxbjDhd5NigQ>? NX\MXIY6OSC2bzC0JIhzew>? MVXJcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IGDES2ZT[mW2YTCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBj[WO3bH;2bZJ2eyCrbn\lZ5Rm\CCrboPlZ5Qh[2WubIOgeZNqdmdiYnnveIlvgWyjdHXkJJBmeHSrZHWgd5Vje3S{YYTlJGdIVE[GRGDTXXZPXlGQTDDpckBxemW|ZX7j[UBw\iCDVGCgbY5kfWKjdHXkJIZweiBzIITvJFQhcHK|IHL5JJRqdWVicnXzc4x3\WRiZnz1c5Jme2OnbnPlJIF{e2G7LDDJR|UxRTBwMECx{txO Mn;VQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd7MUSzOlIoRjJ5OUG0N|YzRC:jPh?=
Sf9 MmXYSpVv[3Srb36gZZN{[Xl? NV3GfItJOSC2bzC0JIhzew>? NXr4[WZLUW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBpfW2jbjDOMZRmem2rbnHsJGdUXC:KaYO2MZRi\2enZDDjMWtKXCBqNUS0JJRwKDl5NjDy[ZNq\HWnczmg[ZhxemW|c3XkJIlvKGKjY4Xsc5ZqenW|IHnu[oVkfGWmIIPmPUBk\WyuczD1d4lv\yCkaX;0bY56dGG2ZXSgdIVxfGmmZTDzeYJ{fHKjdHWgS2dNTkSGUGPZWm5XWU6OIHnuJJBz\XOnbnPlJI9nKEGWUDDpcoN2[mG2ZXSg[o9zKDFidH:gOEBpenNiYomgeIlu\SC{ZYPvcJZm\CCobIXvdoV{[2WwLDDJR|UxRTBwMECx{txO MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzlzNEO2Nkc,Ojd7MUSzOlI9N2F-
Sf9 M2rBbGZ2dmO2aX;uJIF{e2G7 MX[xJJRwKDRiaILz MnTmTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDoeY1idiCQLYTldo1qdmGuIFfTWE9JcXN4LYTh[4dm\CCITGSzJEg2PzFidH:gPVk{KHKnc3nkeYV{MSCneIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMhcW6oZXP0[YQhe2Z7IHPlcIx{KHW|aX7nJIJqd3SrbonsZZRm\CCyZYD0bYRmKHO3YoP0doF1\SCJR1zGSGRRW1mYTm\RUmwhcW5icILld4Vv[2Vib3[gRXRRKGmwY4XiZZRm\CCob4KgNUB1dyB2IHjyd{BjgSC2aX3lJJJme2:udnXkJIZtfW:{ZYPj[Y5kNCCLQ{WwQVAvODBzzszN NHTBb2s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{mxOFM3Oid-Mke5NVQ{PjJ:L3G+
insect cells M3PmTWZ2dmO2aX;uJIF{e2G7 NGLCcFYyKHSxIESgbJJ{ NVfQZ|FXUW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBHT0[UMTCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBj[WO3bH;2bZJ2eyCrbn\lZ5Rm\CCrboPlZ5Qh[2WubIOgeZNqdmdiYnnveIlvgWyjdHXkJJBmeHSrZHWgd5Vje3S{YYTlJGdIT0eTRFfLSHlKXkySSTDpckBxemW|ZX7j[UBw\iCDVGCgbY5kfWKjdHXkJIZweiBzIITvJFQhcHK|IHL5JJRqdWVicnXzc4x3\WRiZnz1c5Jme2OnbnPlJIF{e2G7LDDJR|UxRTBwMEC4{txO MlizQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd7MUSzOlIoRjJ5OUG0N|YzRC:jPh?=
insect cells M1PweGZ2dmO2aX;uJIF{e2G7 Ml7TNUB1dyB2IHjydy=> MkXXTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDWSWdHWjNiKIXub45wf25ib4Lp[4lvMSCneIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMhcW6oZXP0[YQhcW6|ZXP0JINmdGy|IIXzbY5oKGKrb4Tpcplt[XSnZDDw[ZB1cWSnIIP1ZpN1emG2ZTDHS2dIWUSJS1TZTXZNWEliaX6gdJJme2WwY3Wgc4YhSVSSIHnuZ5Vj[XSnZDDmc5IhOSC2bzC0JIhzeyCkeTD0bY1mKHKnc3;seoVlKG[udX;y[ZNk\W6lZTDhd5NigSxiSVO1NF0xNjByON88US=> Ml25QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd7MUSzOlIoRjJ5OUG0N|YzRC:jPh?=
insect cells M2nMd2Z2dmO2aX;uJIF{e2G7 MlT0NUB1dyB2IHjydy=> NEjDTI5KdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JHZGT0[UMTCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBj[WO3bH;2bZJ2eyCrbn\lZ5Rm\CCrboPlZ5Qh[2WubIOgeZNqdmdiYnnveIlvgWyjdHXkJJBmeHSrZHWgd5Vje3S{YYTlJGdIT0eTRFfLSHlKXkySSTDpckBxemW|ZX7j[UBw\iCDVGCgbY5kfWKjdHXkJIZweiBzIITvJFQhcHK|IHL5JJRqdWVicnXzc4x3\WRiZnz1c5Jme2OnbnPlJIF{e2G7LDDJR|UxRTBwMEJOwG0> M4TRTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OUG0N|YzLz5{N{mxOFM3OjxxYU6=
insect cells MXTGeY5kfGmxbjDhd5NigQ>? Mn62NUB1dyB2IHjydy=> NETqN4RKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JHZGT0[UMjCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBj[WO3bH;2bZJ2eyCrbn\lZ5Rm\CCrboPlZ5Qh[2WubIOgeZNqdmdiYnnveIlvgWyjdHXkJJBmeHSrZHWgd5Vje3S{YYTlJGdIT0eTRFfLSHlKXkySSTDpckBxemW|ZX7j[UBw\iCDVGCgbY5kfWKjdHXkJIZweiBzIITvJFQhcHK|IHL5JJRqdWVicnXzc4x3\WRiZnz1c5Jme2OnbnPlJIF{e2G7LDDJR|UxRTBwMEGz{txO MlLyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd7MUSzOlIoRjJ5OUG0N|YzRC:jPh?=
TC32 M3rMSZFJXFNiYYPzZZk> NFXvTZhyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiVFOzNkBk\Wyucx?= MmLPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
SJ-GBM2 NFjS[m5yUFSVIHHzd4F6 MVrxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0pvR1LNNkBk\Wyucx?= MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
A673 NGfnN|hyUFSVIHHzd4F6 NVXESHRweUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFG2O|Mh[2WubIO= NVW2c3piRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-MC NGnOVVZyUFSVIHHzd4F6 NWTOboo1eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGPLMW4uVUNiY3XscJM> NU\C[GpsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-37 MUfxTHRUKGG|c3H5 MmDDdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKEKWLUO3JINmdGy| NWHQXnBxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB-EBc1 M3vv[ZFJXFNiYYPzZZk> NWnPWGV5eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IF7CMWVD[zFiY3XscJM> M37PfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
U-2 OS MVTxTHRUKGG|c3H5 M2LKO5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCXLUKgU3Mh[2WubIO= MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
Saos-2 NV7DN|ZjeUiWUzDhd5NigQ>? NI[3TGpyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU3Hvd{0zKGOnbHzz MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
SK-N-SH NW\VOGE6eUiWUzDhd5NigQ>? MYnxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3TTEBk\Wyucx?= Mly2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
NB1643 M3PSbJFJXFNiYYPzZZk> M1PZWZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQkG2OFMh[2WubIO= NV35VWVrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
LAN-5 NH;vcW9yUFSVIHHzd4F6 MWDxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVEGQLUWgZ4VtdHN? Ml35QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
BT-12 MWfxTHRUKGG|c3H5 NVPDVnZYeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFLUMVEzKGOnbHzz MlfLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
Rh18 NGjTTWJyUFSVIHHzd4F6 Mlf1dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqMUigZ4VtdHN? MmnGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
OHS-50 NXvUVZBDeUiWUzDhd5NigQ>? M17l[JFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCRSGOtOVAh[2WubIO= NIrDeY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
RD MXfxTHRUKGG|c3H5 M1TSW5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCURDDj[Yxtew>? M2rVXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
insect cells MmjESpVv[3Srb36gZZN{[Xl? MYOxJJRwKDRiaILz MVXJcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IF\HSnIyKCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIHLhZ5Vtd3[rcoXzJIlv\mWldHXkJIlve2WldDDj[YxteyC3c3nu[{BIT0eJUVTHT2R[UV[OUFmgZZMhe3Wkc4TyZZRmKGGodHXyJFEhfG9iNDDodpMh[nlidHnt[U1z\XOxbI\l[EBndHWxcnXzZ4Vv[2ViYYPzZZktKEmFNUC9NE4xODkQvF2= Mnr5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB3MEO5N|goRjNyNUCzPVM5RC:jPh?=
NCI-H1703 NU\WWIdYTnWwY4Tpc44h[XO|YYm= NELmXFAyOCC3TR?= NYT3OYFZOjRiaILz MkTsTY5pcWKrdHnvckBw\iCWTlnLJIlvKGi3bXHuJG5EUS2KMUewN{Bk\WyuczD0doFve2[nY4Tl[EB4cXSqIHzlcpRqfmm{YXygeoVkfG:{IEfUSnAh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIH;mJGdUUzNiaX7obYJqfG:{IGigZYN1cX[jdHXkJHRPUUtvbXXkbYF1\WRiV370M3RETi:kZYThMYNifGWwaX6t[IVx\W6mZX70JJRz[W6|Y4LpdJRqd25iYYSgNVAhfU1iYX\0[ZIhOjRiaILzJIJ6KGy3Y3nm[ZJie2VicnXwc5J1\XJiYYPzZZk> Mmj5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIzQDl{Lze+R4hGVUKOPD;hQi=>
LoVo MXHDfZRwfG:6aXPpeJkh[XO|YYm= Mnj0NVAhfU1? M4rVW|czKGi{cx?= NXjIdWk2S3m2b4TvfIlkcXS7IHHnZYlve3RiV370M4JmfGFvY3H0[Y5qdiC|aXfuZYxtcW6pIHTldIVv\GWwdDDoeY1idiCOb2\vJINmdGy|IHHzd4V{e2WmIHHzJINmdGxidnnhZoltcXS7IHH0JFExKHWPIHHmeIVzKDd{IHjyd{BjgSCDVGDsbZRmKGG|c3H5 Ml;GQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIzQDl{Lze+R4hGVUKOPD;hQi=>
HCT116 NYDmVpQ4S3m2b4TvfIlkcXS7IHHzd4F6 MWKxNEB2VQ>? MWi3NkBpenN? NXjCSZVOS3m2b4TvfIlkcXS7IHHnZYlve3RiV370M4JmfGFvY3H0[Y5qdiC|aXfuZYxtcW6pIHTldIVv\GWwdDDoeY1idiCKQ2SxNVYh[2WubIOgZZN{\XO|ZXSgZZMh[2WubDD2bYFjcWyrdImgZZQhOTBidV2gZYZ1\XJiN{KgbJJ{KGK7IFHUVIxqfGViYYPzZZk> MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlI5QTJxJ{7DbGVOSkx:L3G+

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
CDK1 / p-CDK1 / p53 / p21 ; 

PubMed: 24238094     


(A) Dovitinib induces phosphorylation of CDK1(Tyr15) in nasopharyngeal carcinoma cells. HONE1 cells were incubated with Dovitinib (5 μM) and harvested at the indicated time-points. Lysates were prepared and the indicated proteins were detected with immunoblotting. Equal loading of lysates was confirmed by immunoblotting for actin. (B) Dovitinib induces phosphorylation of CDK1Tyr15 in HeLa cells. HeLa cells were exposed to the indicated concentrations of Dovitinib for 24 hrs. Lysates were prepared and analysed with immunoblotting. Equal loading of extracts was accessed by immunoblotting of actin. (C) Dovitinib induces phosphorylation of CDK1Tyr15 in Hep3B cells. Hep3B cells were treated with the indicated concentrations of Dovitinib for 24 hrs. Lysates were prepared for immunoblotting analysis. Actin was probed to confirm equal loading. 

p-PDGFR-β / PDGFR-β / p-ERK / ERK ; 

PubMed: 23228017     


Phosphorylation of p-PDGFR-β and p-ERK were inhibited by dovitinib at pharmacologically relevant concentrations in MHCC-97H and SMMC7721 cells.

p-VEGFR-2 / VEGFR-2 / p-FGFR-1 / FGFR-1 ; 

PubMed: 23228017     


Dovitinib inhibited the phosphorylation of FGFG-1, VEGFR-2, and downstream ERK in HMVEC and HUVEC endothelial cells at pharmacologically relevant concentrations.

p-STAT3 / STAT3 / Mcl-1 / LC3 / Beclin 1 / p62 ; 

PubMed: 31485222     


The protein extracts from dovitinib-treated were subjected to immunoblot analysis for p-STAT3, STAT3, Mcl-1, beclin1, LC3B, p62, and actin.

24238094 23228017 31485222
Growth inhibition assay
Cell viability; 

PubMed: 28467797     


Cell viability of peripheral blood mononuclear cells (PBMCs) and RPMI8226 cells treated with dovitinib in RPMI1640 medium containing 5% FBS for 24 h. Data are presented as mean±SD. Experiments were performed in triplicate.* P < 0.01, **P < 0.001 versus control.

28467797
In vivo Dovitinib induces both cytostatic and cytotoxic responses in vivo resulting in regression of FGFR3-expressing tumors.[1] Dovitinib shows a dose- and exposure-dependent inhibition of target receptor tyrosine kinases (RTKs) expressed in tumor xenografts. Dovitinib potently inhibits tumor growth of six HCC lines. Inhibition of angiogenesis correlated with inactivation of FGFR/PDGFRβ/VEGFR2 signaling pathways. In an orthotopic model, Dovitinib potently inhibits primary tumor growth and lung metastasis and significantly prolonged mouse survival. [2] Administration of Dovitinib results in significant tumor growth inhibition and tumor regressions, including large, established tumors (500-1,000 mm3). [3]

Protocol

Kinase Assay:[1]
- Collapse

In vitro kinase assays:

The inhibitory concentration of 50% (IC50) values for the inhibition of RTKs by Dovitinib are determined in a time-resolved fluorescence (TRF) or radioactive format, measuring the inhibition by Dovitinib of phosphate transfer to a substrate by the respective enzyme. The kinase domains of FGFR3, FGFR1, PDGFRβ, and VEGFR1-3 are assayed in 50 mM HEPES (N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid), pH 7.0, 2 mM MgCl2, 10 mM MnCl2 1 mM NaF, 1 mM dithiothreitol (DTT), 1 mg/mL bovine serum albumin (BSA), 0.25 μM biotinylated peptide substrate (GGGGQDGKDYIVLPI), and 1 to 30 μM adenosine triphosphate (ATP) depending on the Km for the respective enzyme. ATP concentrations are at or just below Km. For c-KIT and FLT3 reactions the pH is raised to 7.5 with 0.2 to 8 μM ATP in the presence of 0.25 to 1 μM biotinylated peptide substrate (GGLFDDPSYVNVQNL). Reactions are incubated at room temperature for 1 to 4 hours and the phosphorylated peptide captured on streptavidin-coated microtiter plates containing stop reaction buffer (25 mM EDTA [ethylenediaminetetraacetic acid], 50 mM HEPES, pH 7.5). Phosphorylated peptide is measured with the DELFIA TRF system using a Europium-labeled antiphosphotyrosine antibody PT66. The concentration of Dovitinib for IC50 is calculated using nonlinear regression with XL-Fit data analysis software version 4.1 (IDBS). Inhibition of colony-stimulating factor-1 receptor (CSF-1R), PDGFRα, insulin receptor (InsR), and insulin-like growth factor receptor 1 (IGFR1) kinase activity is determined at ATP concentrations close the Km for ATP.
Cell Research:[1]
- Collapse
  • Cell lines: B9 cells, MM cell lines
  • Concentrations: 100 nM
  • Incubation Time: 48-96 hours
  • Method: Cell viability is assessed by 3-(4,5-dimethylthiazol)-2,5-diphenyl tetrazolium (MTT) dye absorbance. Cells are seeded in 96-well plates at a density of 5 × 103 (B9 cells) or 2 × 104 (MM cell lines) cells per well. Cells are incubated with 30 ng/mL aFGF and 100 μg/mL heparin or 1% IL-6 where indicated and increasing concentrations of Dovitinib. For each concentration of Dovitinib, 10 μL aliquots of drug or DMSO diluted in culture medium is added. For drug combination studies, cells are incubated with 0.5 μM dexamethasone, 100 nM Dovitinib, or both simultaneously where indicated. To evaluate the effect of Dovitinib on growth of MM cells adherent to BMSCs, 104 KMS11 cells are cultured on BMSC-coated 96-well plates in the presence or absence of Dovitinib. Plates are incubated for 48 to 96 hours. For assessment of macrophage colony-stimulating factor (M-CSF)-mediated growth, 5 × 103 M-NFS-60 cells/well are incubated with serial dilutions of Dovitinib with 10 ng/mL M-CSF and without granulocyte-macrophage colony-stimulating factor (GM-CSF). After 72 hours cell viability is determined using Cell Titer-Glo Assay. Each experimental condition is performed in triplicate.
    (Only for Reference)
Animal Research:[1]
- Collapse
  • Animal Models: 8-week-old female BNX mice bearing KMS11 cells
  • Dosages: 10, 30, or 60 mg/kg
  • Administration: Gavage
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 30 mg/mL (76.44 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% PEG400+0.5% Tween80+5% propylene glycol
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 392.43
Formula

C21H21FN6O

CAS No. 405169-16-6
Storage powder
in solvent
Synonyms CHIR-258
Smiles CN1CCN(CC1)C2=CC3=C(C=C2)N=C(N3)C4=C(C5=C(C=CC=C5F)NC4=O)N

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT01700270 Completed Drug: dovitinib (TKI258)|Drug: fluvoxamine Advanced Solid Tumors Excluding Breast Cancer Novartis Pharmaceuticals|Novartis May 2013 Phase 1
NCT01680796 Withdrawn Drug: Dovitinib|Drug: Bortezomib|Drug: Dexamethasone Multiple Myeloma University of Florida|Novartis Pharmaceuticals February 2013 Phase 1
NCT01576380 Completed Drug: TKI258 Adenocarcinoma Scirrhous|Linitis Plastica|Stomach Neoplasms|Stomach Diseases|Neoplasms by Site|Neoplasms Novartis Pharmaceuticals|Novartis June 2012 Phase 2
NCT01791387 Unknown status Drug: Dovitinib Clear Cell Renal Cell Carcinoma Auckland District Health Board|University of Auckland New Zealand|IGENZ Ltd. Auckland|Novartis March 2012 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

FLT3 Signaling Pathway Map

FLT3 Inhibitors with Unique Features

Related FLT3 Products

Tags: buy Dovitinib (TKI-258) | Dovitinib (TKI-258) supplier | purchase Dovitinib (TKI-258) | Dovitinib (TKI-258) cost | Dovitinib (TKI-258) manufacturer | order Dovitinib (TKI-258) | Dovitinib (TKI-258) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID